Neuregulins are important growth factors involved in cardiac development and response to stress. Certain isoforms and fragments of neuregulin have been found to be cardioprotective. The effects of a full-length neuregulin-1β isoform, glial growth factor 2 (GGF2; USAN/INN; also called cimaglermin) were investigated in vitro. Various dosing regimens were then evaluated for their effects on left ventricular (LV) function in rats with surgically-induced myocardial infarction. In vitro, GGF2 bound with high affinity to erythroblastic leukemia viral oncogene (ErbB) 4 receptors, potently promoted Akt phosphorylation, as well as reduced cell death following doxorubicin exposure in HL1 cells. Daily GGF2 treatment beginning 7-14 days after left anterior descending coronary artery ligation produced improvements in LV ejection fraction and other measures of LV function and morphology. The improvements in LV function (e.g. 10% point increase in absolute LV ejection fraction) with GGF2 were dose-dependent. LV performance was substantially improved when GGF2 treatment was delivered infrequently, despite a serum half-life of less than 2 h and could be maintained for more than 10 months with treatment once weekly or once every 2 weeks. These studies confirm previous findings that GGF2 may improve contractile performance in the failing rat heart and that infrequent exposure to GGF2 may improve LV function and impact remodeling in the failing myocardium. GGF2 is now being developed for the treatment of heart failure in humans.
Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequency on left ventricular function in rats following myocardial infarction Neuregulin growth factors are essential to the normal development and function of the brain and myocardium (Falls, 2003; Gassmann et al., 1995; Lee et al., 1995) . Dysfunction of the neuregulin-1 (NRG1) gene or its cognate ErbB receptors (i.e. neuregulin ErbB2 receptor gene deletion) results in abnormal cardiac development and embryonic lethality (Gassmann et al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995) . The clinical importance of NRG1/ErbB signaling in maintaining normal myocardial function was highlighted by the observation that patients receiving the anti-ErbB2 antibody trastuzumab exhibited cardiac dysfunction, particularly when given concomitantly with anthracyclines (Slamon et al., 2001) .
NRG1 isoforms are expressed in cardiac endothelial cells (Cote et al., 2005; Rohrbach et al., 1999; Zhao et al., 1998) and interact with ErbB receptors on cardiomyocytes (Falls, 2003) . NRG1 binds to ErbB3 and ErbB4 receptors (the latter preferentially expressed in adult cardiomyocytes), which homodimerize and/or heterodimerize with ErbB2 (Lemmens et al., 2007; Zhao et al., 1998; Ferguson et al., 2000) . ErbB4/ErbB2 dimerization, which promotes ErbB-receptor phosphorylation and activation of multiple downstream kinase pathways, is a requirement for NRG1 signaling in the myocardium (Lemmens et al., 2007; Zhao et al., 1998; Fukazawa et al., 2003; Kuramochi et al., 2006) . Thus, NRG1 may act in a paracrine manner through pathways that promote cardiomyocyte survival, growth, and function.
Neuregulin signaling is critical to both cardiac development and maintenance of normal adult heart function (Pentassuglia and Sawyer, 2009) . In vitro, neuregulins promote survival and inhibit apoptosis of cultured embryonic and neonatal cardiomyocytes (Zhao et al., 1998) . NRG1 also ameliorates drug-induced cardiomyocyte toxicity in culture (Bian et al., 2009; Fukazawa et al., 2003; Kuramochi et al., 2004; Rohrbach et al., 2005b; Sawyer et al., 2002) . In vivo, neuregulins improve left ventricular (LV) function in heart failure induced by myocardial infarction (MI) in multiple species, anthracycline exposure, viral myocarditis, and rapid pacing (Bersell et al., 2009; Bian et al., 2009; Hill et al., 2013; Liu et al., 2006) . These studies suggest that NRG1 may be therapeutically beneficial in treating heart failure.
We report the results of a series of studies that characterize the pharmacologic activity of the full-length neuregulin-1β isoform glial growth factor 2 (GGF2 [USAN/INN; also called cimaglermin]) (Marchionni et al., 1993) in vitro and in vivo. While GGF2 was shown previously to bind to ErbB4 receptors, promote Akt phosphorylation in vitro, and improve LV function in rats following MI (Iaci et al., 2010; Bian et al., 2009; Hill et al., 2013) , the present study: 1) confirms and extends this work by demonstrating the dose-dependency of GGF2 cytoprotection in doxorubicin-treated cardiomyocytes; 2) describes the effects of GGF2 dose level and regimen on LV function in a post-MI heart-failure model in rats; and 3) reports the plasma GGF2 exposure associated with pharmacologic activity. These studies provide a pharmacologic basis for ongoing clinical evaluation of GGF2 in patients with advanced heart failure (Lenihan et al., 2013) .
Materials and methods

Test compounds
GGF2 and a control neuregulin comprising only the epidermal growth factor-like domain fragment of neuregulin-1-β (NRG-EGF) were produced at CMC Biologics, Inc. (Bothell, Washington, USA) and/ or Acorda Therapeutics, Inc. (Ardsley, New York, USA) The cloning, expression, and purification of NRG-EGF and GGF2 are briefly described below.
GGF2
A serum-free production vector and cell line were produced previously and described in United States patent numbers 5530109 and 6051401. The GGF2 coding sequence was confirmed by polymerase chain reaction (PCR)-based sequencing (not shown). Banked Chinese hamster ovary (CHO) cells containing the GGF2 expression vector were expanded within expansion flasks containing chemically defined (CD)-CHO medium (Invitrogen; Life Technologies Corporation, Carlsbad, California, USA) supplemented with iron sulfate•ethylenediaminetetraacetic acid (EDTA), L-glutamine, recombinant human insulin, non-essential amino acids, peptone (Type IV from soybean), and gentamicin until reaching sufficient numbers to seed production vessels (0.3×10 6 cells/ml). Cells in the seeded bioreactor were then grown in CD-CHO/HyQ SFX-CHO (HyClone [1:1]; Thermo Scientific, VWR, Radnor, Pennsylvania, USA) supplemented as above. Cells were maintained in culture at 37°C for 4 days and then 34°C through 14 days, at which time cells were harvested. Harvested material was clarified, sterile filtered, and subjected to various chromatographic steps (below) to obtain purified GGF2. The primary sequence of the expressed GGF2 protein is as follows:
2.1.1.1. Purification. Conditioned media were loaded onto a cation exchange capture column (HiPrep SP 16/10; GE Healthcare BioSciences Corp, Piscataway, New Jersey, USA) with 20 mM sodium acetate and 350 mM sodium chloride (pH 6.0). The GGF2 fraction was eluted with 20 mM sodium acetate and 600 mM sodium chloride (pH 6.0). The GGF2 was further purified by gel filtration (HiPrep 26/60 Sephacryl S-200 High Resolution; GE Healthcare Bio-Sciences Corp). DNA and endotoxin were removed with Millipore's Intercept Q membrane filtration, and the resulting protein solution was sterile filtered.
NRG-EGF control neuregulin
The NRG1-β−2 EGF-like domain (NRG-EGF) was cloned from human brain cDNA into the pET-15b vector (Novagen, Inc., Madison, Wisconsin, USA) using Nde1 and BamH1 restriction sites, and the sequence was confirmed by PCR-based sequencing (data not shown). The vector was inserted into Escherichia coli, and the resulting nonglycosylated recombinant protein was expressed. The NRG-EGF protein has a theoretical isoelectric point/molecular weight: 7.69/9-10 kDa (6.92 kDa +~3 kDa histidine [His]-tag).
BL21 cells were transformed and incubated using the Overnight Express Autoinduction System (Novagen, Inc.) in Luria Broth EZMix (Sigma-Aldrich, Inc., St. Louis, Missouri, USA) at 25°C for 24 h. The expressed protein was solubilized and refolded using a protocol adapted from Novagen (Protein Refolding Kit). The solubilized protein was purified using a diethylaminoethyl (DEAE) flow-through column. The loading and washing buffer was 50 mM Tris-buffered saline (TBS; pH 7.9), and elution buffer was 50 mM TBS (pH 7.9) with 1 M sodium chloride. The flow-through was pooled and concentrated with Centriprep YM-3 (Millipore, Bedford, Massachusetts, USA). The Histag was removed with the Thrombin Cleavage Capture Kit (Novagen) and NRG-EGF recovered with sterile spin filtration. Complete cleavage was confirmed with an anti-EGF polyclonal antibody (Anti-EGF Human NRG1-α/heme-responsive gene 1 protein-α, Affinity Purified Polyclonal Antibody [1:1000 dilution]; R & D Systems, Inc., Minneapolis, Minnesota, USA) and anti-His Western blotting. The final translated NRG-EGF fragment primary sequence is shown below:
MSHLVKCAEK EKTFCVNGGE CFMVKDLSNP SRYLCKCPNE FTGDRCQNYV MASFYKAEEL YQ.
Vehicle
The vehicle/control used in early in vivo studies was 0.1 M sodium phosphate (pH 7.6). Bovine serum albumin (BSA; 0.2%) was added to the vehicle control only for studies involving NRG-EGF for comparison, as BSA was necessary to stabilize the NRG-EGF fragment. The vehicle used in long-term dose regimen studies also contained 100 mM arginine, 20 mM histidine, 100 mM sodium sulfate, and 1% mannitol in deionized water buffered at a pH of 6.5.
In vitro studies
Competition binding assay
A competition binding assay using immunodetection of a betacellulin probe ligand (a naturally occurring ErbB receptor ligand) was used to evaluate binding affinity of GGF2 or NRG-EGF for the ErbB4 receptor in a 96-well high-binding plate (Corning Costar; SigmaAldrich, Inc., St Louis, Missouri, USA). Wells were coated with recombinant human ErbB4/Fc chimera (R & D Systems, Inc.) at a concentration of 500 ng/ml in phosphate-buffered saline (PBS) overnight at room temperature. After washing and blocking, standards and test samples were added in a 1% BSA (Sigma-Aldrich, Inc.) diluent containing recombinant human betacellulin at 2 ng/well (R & D Systems, Inc.) for 1 h at 37°C. After washing, biotinylated anti-human betacellulin antibody was added (0.2 μg/ml with 2% normal goat serum; R & D Systems, Inc.) for 1 h at 37°C. Plates were washed, and the biotinylated antibody was detected with streptavidin-horseradish peroxidase (HRP)and 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (DY998; R & D Systems, Inc.) as per the manufacturer's instructions. Development was stopped with 1 M phosphoric acid, and the absorbance of each well was read at 450 nm. Data were plotted as absorbance versus log concentration of competing ligand (GGF2 or NRG-EGF). Binding data were fit using a four-parameter logistic equation for the calculation of half maximal inhibitory concentration (IC 50 ; GraphPad Prism version 5.0 software).
Bioactivity assay
Binding Inc.) . Cells plated at 20,000 cells per well in 96-well plates were switched to serum-free medium and exposed to test article or controls for 7 min at 37°C and 5% carbon dioxide. The cells were then fixed with formaldehyde at room temperature. Akt and phosphorylated Akt were detected according to the kit manufacturer's instructions. Well fluorescence was read at 540 nm excitation and 600 nm emission using a Molecular Devices M2 Plate Reader (MTX Lab Systems, Inc., Vienna, Virginia, USA). Data were reported as phosphorylated Akt and the ratio of phosphorylated to total Akt as a function of log neuregulin concentration. Data were fit with a standard slope four-parameter logistic equation for half-maximal effective concentration (EC 50 ) determination (GraphPad Prism version 5.0 software). Standard error of the mean (S.E.M.) IC 50 was calculated using the following formula: S.E.(IC 50 ) =(10^log IC 50 ) * S.E.(log IC 50 ) * ln(10), where ln(10) =2.30258509 where ln(10) =2.30258509, and S.E. = S.D./(n-1) ½ .
2.2.3. Cardiomyocyte doxorubicin assay HL-1 cells, derived from the AT-1 mouse atrial cardiomyocyte tumor lineage were plated at 75,000 cells per 0.1 ml of growth medium (Claycomb media, Sigma-Aldrich, Inc.; supplemented with 10% fetal bovine serum, 0.1 mM norepinephrine, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin) per well in 96-well microtiter plates and cultured overnight at 37°C in a humidified, 5% carbon dioxide atmosphere. Cells were then conditioned in a serum-free medium for 6 h. Test samples and controls were added at the reported concentrations in serum-free media. After a 1 h pretreatment, 50 μl of vehicle or doxorubicin (Catalent Clinical Packaging; Catalent Pharma Solutions, Somerset, New Jersey, USA) were added per well for a final doxorubicin concentration of 1 μM for 16-18 h at 37°C and 5% carbon dioxide in a humidified incubator. Cell viability, measured by the reductive capacity of HL-1 cell mitochondria, was determined using 3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide (MTT), which is reduced to formazan (MTT Assay, Sigma-Aldrich, Inc. ) were anesthetized with pentobarbital, intubated, and mechanically ventilated with room air. A craniocaudal incision was made through the skin overlying the ventral chest slightly left of the sternum. The third and fourth ribs were retracted, the pericardium was opened, and the heart was exteriorized through the intercostal space. After identifying the left atrium and pulmonary conus, a 5-0 ligature was placed under the LAD coronary artery using a small needle and tied. The heart was returned to the thoracic cavity and the wound was closed. Air was then evacuated from the thoracic cavity. Animals remained on positive pressure ventilation until emerging from anesthesia, at which time they were extubated and placed in an oxygen-rich environment until ambulatory.
Post-surgical dosing and echocardiographic evaluation
Animals were dosed with vehicle, GGF2, and/or the control NRG-EGF according to the dosing regimens described below and summarized in Table 1 . Rats were echocardiographically monitored at multiple time points post-MI. Studies conducted at MPI Research included the daily dosing and initial dose frequency study (described below); otherwise all other studies were conducted at Acorda Therapeutics, Inc. Animal handling, surgery, dosing, and echocardiographic assessment/analysis were conducted in a manner blinded to the identity of test material.
High-resolution ultrasonography (Visualsonics Vevo 2100, Toronto, Canada) was used to obtain echocardiographic images for Harvested hearts were emersion-fixed in 10% neutral buffered formalin then trimmed into three consecutive 2.5-3 mm segments and paraffin embedded. Heart segments were sectioned at a thickness of approximately 6 µm with one serial section stained with hematoxylin and eosin and another stained with Masson's trichrome to demonstrate infarcted regions. Heart tissue was assessed for the percentage of the LV free wall that was infarcted (i.e., replaced by fibrous connective tissue) or where myocardial fibers were necrotic by a board-certified veterinary pathologist blinded to experimental conditions.
In a separate study designed to determine whether the presence of BSA in the vehicle influenced pharmacologic activity of GGF2, animals were dosed via tail vein daily from post-MI days 8-17 with vehicle or GGF2 at 50 nmol/kg/dose (3.25 mg/kg) with or without 0.2% BSA in PBS. Again, echocardiographic assessment was conducted on post-MI days 1, 7 (pretreatment), 28, and 38.
These two studies were conducted at MPI Research.
2.3.4.2. Effect of daily, every-other-day, or every-fourth-day GGF2 administration. Animals were dosed with vehicle (0.1 M PBS) or 50 nmol/kg (3.25 mg/kg) of GGF2 in 0.1 M PBS without BSA every day (every 24 h), every other day (every 48 h), or every fourth day (every 96 h) from post-MI days 8-27 via the tail vein. Echocardiographic assessment was conducted on post-MI days 1, 7 (pretreatment), 28, and 38. This study was conducted at MPI Research.
2.3.4.3. Effect of delayed GGF2 treatment followed by cessation and re-initiation of treatment. At 20 weeks post-MI, rats were randomly assigned to receive intravenous vehicle (comprising 20 mM histidine, 100 mM arginine, 100 mM sodium sulfate, 1% mannitol; this vehicle was used in this and subsequent studies) or GGF2 treatment (2.6 mg/ kg; dose selected in the context of change in vehicle formulation and pharmacologic activity observed in pilot studies) twice weekly for 1 month. Following the treatment period, rats then entered a 1-month treatment-free period followed by a vehicle-treatment or GGF2-retreatment period that was similar to the first treatment period. Echocardiographic parameters were assessed at least once weekly for 12 weeks, with twice weekly monitoring during the washout period. This and the remaining studies were conducted at Acorda Therapeutics, Inc.
2.3.4.4. Effects of once-weekly dosing of GGF2 compared with oncedaily dosing of NRG-EGF. Since twice weekly GGF2 dosing appeared to improve LV function, the effects of once weekly dosing of GGF2 vs daily dosing of NRG-EGF were compared. Animals were assigned to treatment groups based on pre-dose EF (each dose group had similar mean EF and variance before dosing of vehicle, GGF2, or NRG-EGF control) and were dosed intravenously with vehicle (once daily or once weekly), GGF2 (once weekly), or NRG-EGF (once daily) for a total of 6 weeks. Neuregulins were dosed at 2.6 mg/kg for GGF2 and 0.25 mg/kg for NRG-EGF (each approximately 40 nmol/kg). Echocardiographic assessment was conducted once weekly for 6 weeks approximately just prior to the subsequent daily or weekly dose.
2.3.4.5. Effects of chronic GGF2 dosing regimens. Animals assigned to treatment groups based on minimizing the variance in pretreatment EF were dosed with vehicle (containing arginine, histidine, sodium sulfate, and mannitol) or GGF2 at a dose level of 2.6 mg/kg (50 nmol/ kg) either once weekly or once every 2 weeks for 40 weeks beginning approximately 2 weeks after the surgically-induced MI. Echocardiographic assessment was conducted weekly (beginning just prior to dosing for dose-group assignment based on EF as described above), every other week, or monthly. Finally, the dose-dependency of the effects of GGF2 on LV function was evaluated using a once-every-2-week dosing regimen over a dose range of 0.35-3.5 mg/kg (5.38-53.8 nmol/kg).
Pharmacokinetic study
Rats were dosed once intravenously (bolus, tail vein) with either vehicle or GGF2 at dose levels of 0.5, 3.5, or 7.0 mg/kg (7.7, 53.8, or 107.7 nmol/kg, respectively). Dose volumes for either vehicle or GGF2 were 5 ml/kg. Blood samples (approximately 0.5 ml) were collected from an indwelling jugular vein cannula (approximately 10 μl catheter dead space volume allowance) for determination of the plasma concentrations of the test article.
Samples were collected prior to dosing and at approximately 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h post-dose using two cohorts of rats to establish the full-time course (one cohort for 0.083, 0.5, 2, and 8 h and a second cohort for 0.25, 1, 4, and 24 h). The blood samples were placed in lithium heparin-containing tubes and centrifuged under refrigeration. The resulting plasma was separated and stored frozen at approximately −70°C until analyzed for GGF2 concentration by ELISA. At the conclusion of the study, animals were euthanized by overexposure to carbon dioxide according to accepted American Veterinary Medical Association Euthanasia procedures.
2.4.1. Enzyme-linked immunosorbent assay (ELISA) for GGF2 in rat plasma and calculation of GGF2 pharmacokinetic parameters A sandwich-format ELISA was used to determine GGF2 concentration in lithium heparin plasma of Sprague Dawley rats. A goat anti-GGF2 capture antibody (R & D Systems, Inc.) diluted to 1 μg/ml in coating buffer (50 mM sodium carbonate, pH 9.6) was dispensed (0.1 ml per well) into C8 StarWell MaxiSorp microtiter plates (Nunc, Thermo Fisher Scientific Inc., Rochester, New York, USA) and incubated at room temperature for 1 h. Plates were rinsed three times with 0.3 ml per well with TBS saline (pH 8.0). Wells were blocked by addition of 0.3 ml TBS supplemented with 1% BSA and 5% sucrose per well and a 1-to 3-h room temperature incubation with gentle shaking. Plates were rinsed and samples dispensed into the assay wells (0.1 ml per well). Plates were incubated for 1 h at room temperature with gentle shaking and aspirated and wells were rinsed. Detection antibody was added (0.2 μg/ml of biotinylated anti-NRG1-β, R & D Systems, Inc. in TBS [pH 8.0] supplemented with 1% BSA and 2% normal goat serum) and incubated for 1 h at room temperature with gentle shaking. Wells were rinsed, 0.1 ml of a 1:30,000 dilution of streptavidin-HRP (Southern Biotech, Birmingham, Alabama, USA) in TBS (pH 8.0) supplemented with 1% BSA were added and incubated for 30 min at room temperature with gentle shaking. Wells were again rinsed and 0.1 ml of TMB substrate solution (a 1:1 mixture of TMB peroxidase substrate: peroxidase substrate solution B [TMB 2-Component Microwell Peroxidase Substrate Kit; KPL, Inc., Gaithersburg, Maryland, USA]) were incubated at room temperature with gentle shaking for 5-15 min. Final color development was produced by addition of 0.1 ml of 1 M phosphoric acid, followed within 30 min by measurement of OD 450 (HRP product absorbance).
Mean rat pharmacokinetic parameters were calculated via noncompartmental modeling of plasma GGF2 concentration-time data (WinNonlin version 5.2.1; Pharsight Corporation, Sunnyvale, California, USA). Variability in parameters was not calculated because cohorts of rats (three males per dose group) were used to establish mean plasma concentration values at each time point (0.083, 0.25, 1, 2, 4, 6, 8, and 24 h), which were then used to establish a single mean parameter value.
Statistical analysis
Statistical tests for significant differences in mean echocardiographic parameters were established a priori. These tests included either one-way analysis of variance (ANOVA) at each time point followed by a Bonferroni post-test comparing all treatment groups for the daily dosing, initial dose frequency and BSA vehicle studies (MPI studies) or a repeated measures ANOVA followed by a Dunnett's post-test comparing treatment groups with a control (vehicle) for the remaining studies. All statistical comparisons were made assuming an α value of 0.05 using GraphPad Prism software (version 4.03).
Results
As predicted from the amino acid sequence, the control NRG-EGF ligand comprising the EGF binding domain of neuregulin-1β, is a peptide of 6.92 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; (Iaci et al., 2010) . In contrast, the fully glycosylated form of GGF2 has a molecular weight of approximately 65-70 kDa (Iaci et al., 2010) , which is slightly larger than predicted based on the amino acid sequence alone (52.6 kDa). When glycosylation residues are enzymatically removed, the molecular weight of fully deglycosylated GGF2 is~50 kDa as determined using SDS-PAGE (data not shown). Silver staining reduced SDS-PAGE confirming purity, and the concentration of the final formulation was determined by ultraviolet spectroscopy.
3.1. In vitro evaluation 3.1.1. ErbB receptor-binding comparison GGF2 and the control NRG-EGF ligand were compared for their ability to bind to recombinant ErbB4 homodimeric receptors. The binding assay was designed to evaluate the relative ability of each ligand to bind surface-adsorbed ErbB4 extracellular domain in competition with the probe ErbB4 binding ligand, betacellulin. The amount of betacellulin bound to ErbB4 homodimers was measured using antibetacellulin immunodetection. GGF2 and NRG-EGF were observed to compete with betacellulin for ErbB4 binding with concentrations that produced IC 50 of betacellulin binding of 23.4 and 584 nM, respectively (Table 2) .
Cell-based signaling assay
The ability of GGF2 and control NRG-EGF ligand to induce phosphorylation of Akt was evaluated in MCF-7 cells that express multiple ErbB receptor subtypes including ErbB2, ErbB3, and ErbB4. GGF2 and NRG-EGF were found to be potent stimulators of Akt phosphorylation (serine 473) as measured by anti-phosphoserine cytochemistry and normalized to total Akt. GGF2 and NRG-EGF stimulated Akt phosphorylation with concentrations producing EC 50 s of 38.9 and 224 nM, respectively (Table 2 ). Maximal phosphorylation was nearly identical for both ligands (data not shown).
Doxorubicin cardiomyocyte protection assay
The relative abilities of GGF2 and the control ligand, NRG-EGF, to protect HL-1 cardiomyocytes from doxorubicin toxicity were compared. GGF2 and NRG-EGF reduced cell death caused by doxorubicin as measured by MTT reduction (Fig. 1 ). GGF2 and NRG-EGF inhibited doxorubicin-induced MTT reduction in a concentration-dependent manner (Table 2 ; Fig. 1 ). Maximal cardiomyocyte protection was nearly identical for both ligands (Table 2; Fig. 1 ). Summary data from each in vitro system are shown in Table 2 . Each in vitro assay was performed between three and seven times. T.J. Parry et al. European Journal of Pharmacology 796 (2017) 76-89 3.2. In vivo evaluation 3.2.1. Effects of GGF2 and NRG-EGF on cardiac function in MIinduced heart failure in rats The differential effects of daily GGF2 and NRG-EGF dosing on LV function in rats with heart failure induced by MI were evaluated. After a 20-d dosing regimen (post-MI days 8-28), LV function was assessed at 10 d intervals through 38 days post-MI. LV function was significantly impaired versus nontreated controls in this study, with surgically naïve and vehicle-treated MI animals exhibiting mean EF ± S.E.M. of 81.57 ± 1.03 and 59.09 ± 4.06, respectively ( Fig. 2A) . Both low and and NRG-EGF treatment groups at all dose levels showed significant improvement in EF compared with vehicle control. GGF2-treated animals also had improvements at all time points during treatment. The effect was partially lost by 10 days after treatment was removed. A significant decline in EF and FS was observed in vehicle-treated animals compared with baseline over this time period (ψP < 0.05), indicating progressive LV dysfunction following MI. (B) Effects of GGF2 and NRG-EGF on mean change in FS (mean ± S.E.M.), and (C) ESV (mean ± S.E.M.) in the same study. Significance is indicated by single, double, and triple symbols for P < 0.05, 0.01, and 0.005, respectively. Mean changes for each treatment group were compared by one-way analysis of variance followed by a post-hoc Bonferroni test. EF, ejection fraction; ESV, end-systolic volume; FS, fractional shortening; GGF2, glial growth factor 2; LV, left ventricular; MI, myocardial infarction; NRG-EGF, epidermal growth factor-like domain fragment of neuregulin-1β; S.E.M., standard error of the mean. 
T.J. Parry et al. European Journal of Pharmacology 796 (2017) 76-89
higher doses of GGF2 (0.65 and 3.25 mg/kg) and NRG-EGF (0.07 mg/ kg) resulted in significant increases in EF at 18 days post-LAD coronary artery occlusion (P < 0.05, 0.01, and 0.05, respectively) compared with vehicle treatment ( Fig. 2A) . At day 28 post-MI, the increases in EF in animals treated with both low and high dose GGF2
were significantly greater compared with those treated with vehicle (P < 0.01 and 0.005, respectively); the mean changes in EF in the NRG-EGF-treated group at 28 days were not significantly different from baseline (day 7) or from the vehicle control at the same time point (28 days). The mean EF of the vehicle control-treated group declined between days 7 and 38 (ψP < 0.05; Fig. 2A ). Similar improvements were seen with FS and ESV, with ESV decreasing to near normal levels during the treatment period ( Fig. 2B and C) . All treatment groups returned toward pretreatment baseline at 10 days after cessation of treatment (Fig. 2) . Histologically, myocardial cross sections through the ventricles at approximately the mid-papillary level revealed no observable infarction in normal control animals (Fig. 3, top panel) while fibrotic scars were observed in myocardial infarcted animals (Fig. 3, bottom panel) from the daily dosing study. In a separate analysis of histological sections obtained from that study, GGF2 produced no significant changes in infarct size relative to vehicle treatment (data not shown).
Confirmation of activity of GGF2 with and without BSA in rat MI model
It was previously reported that the control NRG-EGF ligand was stabilized by the presence of BSA (Bersell et al., 2009) . For this reason, BSA was included in all preparations of GGF2 and NRG-EGF formulations in the above MI studies. Following these initial studies, the question whether the co-administration of BSA was necessary for the effects of GGF2 was examined experimentally. Animals underwent LAD-coronary artery ligation as described and received GGF2 or vehicle in PBS with or without the inclusion of BSA once daily from days 8-18 post-ligation. EF was measured by echocardiography at days 7 (pre-dose) and 18 (following the last dose). Both treatment groups had significant increases in EF compared with vehicle control (P < 0.05), and at a magnitude similar to the above studies (data not shown). All subsequent studies were performed without the addition of BSA.
Effect of GGF2 dose frequency on EF in the failing rat heart after MI
In order to determine the relationship between GGF2 dosing frequency and the improvement in LV function, GGF2 was administered intravenously (50 nmol/kg or 3.25 mg/kg) from post-MI day 8-28 at dosing frequencies of once every 24, 48, or 96 h. NRG-EGF was not evaluated in this study. Control animals received vehicle administered at the maximum frequency of once every 24 h. Echocardiographic parameters were measured on days 7 (pre-dose), 18, 28, and 38. Unlike the above rat MI studies, animals were assigned to treatment groups based upon EF measured on day 7. Animals were assigned before dosing such that mean EF values and variances were similar across treatment groups.
Average (mean) echocardiographic parameters made from normal uninjured animals for normative comparisons are reported as dashed lines in Fig. 4 . Comparatively, MI produced LV dysfunction as Fig. 4 . Effects of GGF2 dosing frequency on EF, FS, and ESV in failing rat hearts. Vehicle (filled circles) or GGF2 (3.25 mg/kg) was dosed intravenously once every 24 h (open diamonds), 48 h (filled diamonds), and 96 h (open circles) over 20 days beginning on day 7 post-MI. Shown are mean (A) EF ± S.E.M., (B) FS ± S.E.M., and (C) ESV ± S.E.M. Normal mean parameter values for the experiment are indicated. GGF2 at all dose frequencies was associated with significant improvement in EF compared with vehicle control at 28 and 38 days post-MI (single, double, and triple symbols indicate P < 0.05, 0.01, and 0.005, respectively; one-way analysis of variance and post-hoc Bonferroni test). GGF2 treatment improved LV function at all time points during treatment (days 8-28) and at 10 days after cessation of therapy (day 38). Vehicle control animals did not exhibit a progressive decline in LV function in this study over the 40-d post-MI timeframe. Group size for each treatment was 10, except GGF2 administered once every 48 hs (n =9). EF, ejection fraction; ESV, end-systolic volume; FS, fractional shortening; GGF2, glial growth factor 2; LV, left ventricular; MI, myocardial infarction; S.E.M., standard error of the mean.
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European Journal of Pharmacology 796 (2017) 76-89 indicated by decreases in EF and FS as well as increased ESV from baseline compared with normal animals. Treatment of rats with GGF2 once every 24, 48, and 96 h resulted in improved EF compared with vehicle controls (Fig. 4A) . EFs from all three treatment groups were significantly different from the time-matched vehicle controls at both the 28-and 38-d time points (P < 0.01). The greatest difference in improved EF was observed at day 38 (10 days after cessation of dosing). EF for GGF2-and vehicle-treated animals was 63-65% and 53%, respectively. Nonsignificant improvements compared with vehicle treatment were observed at the 18-d time point (day 10 of treatment). Similarly, improvements in FS (Fig. 4B) and ESV (Fig. 4C) were observed with GGF2 treatment and maintained for 10 days after cessation of treatment. Changes in EF were also used to compare the number of animals responding to treatment in this study. The number of animals with positive or negative changes in EF following vehicle or GGF2 (pooled dosing cohorts) treatment on day 38 was compared with that of day 7 (before vehicle or GGF2 dosing). Four animals from the vehicle group had a positive change in LV function (EF at day 38 greater than at day 7) while six animals exhibited negative EF changes. In contrast, all 29 of the rats treated with GGF2 at any dose frequency had positive change in EF from days 7-38 post-MI with positive responders in vehicle vs GGF2 treatment groups differing significantly (P < 0.0001 by Fisher's Exact Test).
3.2.4. Effect of delayed GGF2 treatment followed by cessation and reinitiation of treatment in the failing rat heart after MI In order to evaluate the effects of delayed GGF2 treatment on LV function in the failing rat heart, intravenous vehicle or GGF2 treatment was initiated 20 weeks after producing MI (see Fig. 5 ). As expected, MI produced a dramatic worsening of all reported echocardiographic parameters compared with normal controls. It is notable that rats assigned to the GGF2 treatment group had slightly worse LV performance just before treatment than vehicle-treated controls for all measured parameters. Four weeks of twice-weekly GGF2 treatment at 2.6 mg/kg significantly improved EF, FS and ESV compared with vehicle-treated-control animals (P < 0.05 by repeated measures; Fig. 5 ). Improvements in EF, FS and ESV were lost during a 4-week treatment withdrawal period where each parameter reached vehicle control levels. Upon restarting twice weekly GGF2 treatment for a second 4-week regimen, each respective parameter improved in a manner similar to the initial treatment period (Fig. 5) .
Comparison of the effects of weekly GGF2 versus daily NRG-EGF administration
Given the improvements in LV function observed with daily dosing of GGF2 and NRG-EGF (Fig. 2) and with once-every-96-h dosing (Fig. 4) , the effects of administering equimolar doses of GGF2 administered intravenously once weekly versus NRG-EGF administered once daily on echocardiographic endpoints were examined. As expected, MI-induced LV dysfunction (decreased EF and FS, increased ESV) was observed prior to dosing in vehicle and neuregulin treatment groups compared with normal controls (Fig. 6A-C) . EF and FS progressively decreased while ESV progressively increased in vehicletreated animals ( Fig. 6A-C) . Once weekly intravenous administration of GGF2 significantly increased EF and FS (P < 0.05; Fig. 6A and B) Fig. 5 . Effects of washout and re-initiation of GGF2 treatment administered twice weekly on EF, FS, and ESV in failing rat hearts. Twice-weekly intravenous dosing of vehicle (filled circles), or GGF2 twice weekly (2.6 mg/kg, open circles) over 4 weeks post-MI followed by a 4-week washout and 4-week re-treatment period. Shown are mean (A) EF ± S.E.M., (B) FS ± S.E.M., and (C) ESV ± S.E.M. Normal mean parameter values for the experiment are indicated. Data were compared by repeated measures one-way analysis of variance followed by a post-hoc Dunnett's test. EF, FS, and ESV were significantly improved with GGF2 treatment dosed twice weekly over each treatment period compared with vehicle (P < 0.05). EF, ejection fraction; ESV, end-systolic volume; FS, fractional shortening; GGF2, glial growth factor 2; MI, myocardial infarction; S.E.M., standard error of the mean.
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European Journal of Pharmacology 796 (2017) 76-89 compared with vehicle treatment (once daily or weekly) and decreased ESV (P < 0.05; Fig. 6C ) while equimolar daily dosing of NRG-EGF had no significant effect on any of these parameters. At 6 weeks following initiation of dosing, the EF following GGF2 dosing was 55.3 ± 4.1 versus that of 40.3 ± 4.1 for once weekly vehicle treatment.
3.2.6. Effects of infrequent GGF2 dosing and durability of pharmacologic effect in the failing rat heart Given the robust improvements in LV functional parameters produced by GGF2, additional studies were conducted to examine whether infrequent dosing (once weekly or once every 2 weeks) could produce sustained effects in the post-MI failing rat heart over several months. The NRG-EGF variant was not included in these subsequent studies. The effects of chronic intravenous GGF2 dosing on LV function were evaluated for 40 weeks after initiation of once-weekly or onceevery-2-week treatment approximately 7 to 14 days after MI. LV functional data from animals dosed once weekly or once every 2 weeks are depicted in Figs. 7 and 8, respectively.
As in previous studies, animals with MI exhibited significant LV dysfunction (EF, FS, and ESV; Figs. 7A/8A, 7B/8B, and 7C/8C, respectively) compared with normal controls (e.g. reduction in EF of approximately 26-30% EF units). Vehicle-treated animals did not have significant improvement in any LV functional parameter over the two 44-week studies (Figs. 7 and 8) . Once-weekly-and once-every-2-week GGF2 dosing regimens were both effective at significantly improving EF, FS, and ESV (e.g. maximal improvements of approximately 20% EF, 13% FS units, and 50-70 μl at 40 weeks; P < 0.05), and these effects were maintained with treatment. The magnitude of the sustained improvements in each of the reported parameters was similar to that seen with more frequent dosing over shorter durations. The effects of chronic dosing of GGF2 on ESV were greater in the onceweekly compared with the once-every-2-week regimen; however, both once-weekly and once-every-2-week dosing regimens produced significant improvement in the reported parameters. Of note, cessation of dosing at week 40 led to a reversal or partial reversal of the improvements in EF, FS, and ESV by week 44.
Dose-dependency of the effects of GGF2 on LV function in the failing rat heart
Because the once-every-2-week chronic dosing of GGF2 was sufficient to produce significant improvements in LV function in the post-MI rat heart that were sustained with treatment, the dose dependency of the effects on EF, FS, and ESV were examined using this dosing regimen. The effects of various dose levels of GGF2 on EF, FS, and ESV over 16 weeks are shown in Fig. 9A -C. Once-every-2-week intravenous GGF2 treatment led to dose-dependent and significant improvements (ANOVA with repeated measures and Dunnett's posthoc test, P < 0.05) in EF and FS over the 16-week treatment period at all dose levels tested (0.35-3.5 mg/kg; Fig. 9A, B) . The magnitude of the effect at the highest dose tested compared with vehicle was similar to that seen in Figs. 7 and 8. ESV was significantly improved (ANOVA with repeated measures and Dunnett's post-hoc test, P < 0.05) at a once-every-2-week dose of 3.5 mg/kg (Fig. 9C) .
Pharmacokinetics of GGF2 in rats
To begin to understand whether efficacy in the rat heart-failure Fig. 6 . Effects of once-weekly GGF2 vs once-daily NRG-EGF at equimolar doses on EF, FS, and ESV in failing rat hearts. Intravenous dosing of vehicle (once daily (open circles, dashed line) or once weekly (filled circles, solid line), GGF2 once weekly (2.6 mg/kg, filled diamonds, solid line), NRG-EGF once daily (0.25 mg/kg, open diamonds, dashed line) over 6 weeks post-MI. Shown are mean (A) EF ± S.E.M., (B) FS ± S.E.M., and (C) ESV ± S.E.M. Normal mean parameter values for the experiment are indicated. Data were compared by repeated measures one-way analysis of variance. EF, FS, and ESV were significantly improved with GGF2 treatment dosed once weekly over the treatment period (P < 0.05) followed by a post-hoc Dunnett's test. The effects of once-weekly GGF2 administration were significantly improved compared with once-weekly-vehicle administration for all parameters (P < 0.05). NRG-EGF (once daily) had no significant effect on any of these parameters. EF, ejection fraction; ESV, end-systolic volume; FS, fractional shortening; GGF2, glial growth factor 2; MI, myocardial infarction; NRG-EGF, epidermal growth factor-like domain fragment of neuregulin-1-β; S.E.M., standard error of the mean.
T.J. Parry et al.
European Journal of Pharmacology 796 (2017) 76-89 model was dependent on constant receptor occupancy and related to the pharmacokinetic profile of GGF2, a pharmacokinetic study was performed. Rats were treated with GGF2 at doses of 0.5, 3.5, or 7.0 mg/kg (7.7, 53.8, or 107.7 nmol/kg, respectively) . No GGF2 was measured in pre-dose plasma samples or animals receiving vehicle, indicating that endogenous rat GGF2 could not be detected in plasma. Calculated pharmacokinetic parameters for GGF2 administered as a single intravenous bolus are listed in Table 3 . The clearance and halflife of GGF2 were found to be 646-1596 ml/h/kg and between 1.3 and 1.7 h, respectively. GGF2 would therefore not be expected to be detectable in rat plasma during periods where improved LV function was measured. In follow-up studies, the elimination profile of GGF2 in rats was not affected by repeated administration.
Discussion
Here we report the results of a series of studies investigating the potential role of recombinant NRG1 as a treatment for heart failure. Others have shown that daily dosing with NRG1 fragments (Bersell et al., 2009; Liu et al., 2006) improves cardiac function in rodents with heart failure. Although similar and compelling data have been reported for the cardioprotective effects of both GGF2 and NRG-EGF, the size, charge, and domain differences between full-length NRG1, such as GGF2, and NRG-EGF, may result in significant performance differences when compared directly. Indeed, our findings demonstrate higher receptor affinity for GGF2 compared with NRG-EGF, with enhanced activation of signaling and cardiomyocyte protection in vitro that translated into enhanced ability to improve cardiac function in rat models of heart failure. The maintenance of improved cardiac function post-MI with relatively infrequent dosing supports the potential of GGF2 as a practical therapy for heart failure.
The present studies indicate that GGF2 treatment improves ventricular performance in the failing myocardium over prolonged periods after the drug is eliminated from circulation. In fact, it takes 2-3 weeks for the increase in EF to wane following GGF2 treatment (see Fig. 5 ). Inherent in the structure of the full-length GGF2 molecule is a heparinbinding domain that may have a strong influence over its pharmacokinetic and pharmacodynamic properties (Pankonin et al., 2005) . Within the immunoglobulin domain of GGF2 and other neuregulins is a heparin-binding domain that enhances ErbB receptor-binding affinity (Eto et al., 2006) , perhaps explaining the greater affinity of GGF2 for ErbB4 homodimers compared with the NRG-EGF fragment made in bacteria, which lacks an immunoglobulin domain and is nonglycosylated (see Table 3 ). The higher affinity may explain the increased bioactivity of GGF2 compared with NRG-EGF in Akt activation and myocyte survival (Bian et al., 2009; Fukazawa et al., 2003; Lorita et al., 2009) , although further work would be needed to examine whether other signaling pathways affect biological activity (Bian et al., 2009; Sawyer and Caggiano, 2011) .
Differences in receptor binding, size, charge, glycosylation, and heparin binding observed with various neuregulin isoforms may result in differential pharmacodynamics and pharmacokinetics in vivo and subsequent clinical utility. As demonstrated in vitro, the full-length GGF2 exhibited greater receptor potency in cell-based assays. Additionally, there are several domains within full-length NRG1 proteins carrying unique properties such as enhanced receptor affinity, receptor specificity, and heparan sulfate proteoglycan-binding capacity that could alter tissue distribution and residence time (Eto et al., 2006; Pankonin et al., 2005; Stortelers et al., 2002a Stortelers et al., , 2002b . Major differences in the temporal improvements in LV function were observed between GGF2 and the neuregulin fragment, NRG-EGF, the latter Fig. 7 . Effects of chronic once-weekly intravenous GGF2 treatment on EF, FS, and ESV in failing rat hearts. Intravenous dosing of vehicle (filled circles) or GGF2 (open circles) administered once weekly. The last dose was given at week 40. Ventricular function was assessed echocardiographically once weekly for first month followed by once every month thereafter. Echocardiographic parameters obtained 4 days after dosing. Shown are mean (A) EF ± S.E.M., (B) FS ± S.E.M., and (C) ESV ± S.E.M.; (once-weekly dosing). Normal mean parameter values for the experiment are indicated. Data were compared by repeated measures one-way analysis of variance followed by a Dunnett's test. EF, FS, and ESV were significantly improved with GGF2 treatment compared with vehicle over the treatment period (P < 0.05). EF, ejection fraction; ESV, end-systolic volume; FS, fractional shortening; GGF2, glial growth factor 2; S.E.M., standard error of the mean.
comprising only the EGF-binding domain. Indeed, equimolar quantities of GGF2 produced greater improvements EF, FS, and ESV compared with NRG-EGF in multiple studies when dosed using a dosing schedule similar to that used by Liu and colleagues in animal models (Liu et al., 2006) as well as humans (Gao et al., 2010; Jabbour et al., 2011) . Further, the pharmacologic effects of GGF2 observed at longer dosing frequencies than those produced by NRG-EGF illustrate the importance of the various domains inherent to the GGF2 molecule to sustained pharmacologic activity, which was observed for at least 40 weeks. This durable effect might suggest that long-term treatment is not detrimental to cardiac contractility. It is notable that once-weekly or even once-every-2-week dosing of GGF2 improved contractility in the failing rat heart, whereas once-daily NRG-EGF dosing failed to produce a sustainable LV functional improvement.
Of significance, GGF2 produced sustained improvements in EF and FS over 40 weeks with once-weekly or once-every-2-week dosing. This chronic improvement in LV function following administration of the recombinant human GGF2 in rats suggests that neither anti-GGF2 antibodies, known to be formed in rats in the context of nonclinical development studies (data not shown), nor receptor desensitization negatively affect the beneficial effects of GGF2 in the failing rat myocardium. This durability is further illustrated by the improvements seen following re-treatment with GGF2 following a 1-month withdrawal of the drug after 1 month of twice-weekly treatment.
Sustained LV functional changes coupled with the relatively short plasma GGF2 elimination profile suggest that steady-state levels of GGF2 and continuous receptor stimulation are not required to improve LV function. This would be consistent with a mechanism of action involving receptor-mediated activation of longer-term transcriptional changes in cardiomyocytes (Hill et al., 2013; Sawyer and Caggiano, 2011) . In fact, the present studies suggest that continuous receptor occupancy is not necessary for durable pharmacologic activity in the failing myocardium of the rat. Thus, intermittent exposure may be as effective as continuous exposure/receptor occupancy while limiting overall exposure and potential adverse effects that might be associated with continuous elevation of circulating levels of the molecule.
In addition to the effects on EF and FS, consistent improvements in ESV and wall-thickness (data not reported) were observed with longterm dosing, suggesting that GGF2 may reverse negative remodeling. While other studies have shown that GGF2 reverses negative remodeling by reducing myofibroblast gene expression related to the formation and deposition of extracellular matrix (Galindo et al., 2014) , additional studies are needed to determine mechanisms related to remodeling.
Several mechanisms have been proposed for neuregulin improvement of ventricular function in animal models of heart failure. Cell proliferation is unlikely to be entirely responsible for the neuregulin treatment effect, as the improvements in failing rat hearts seen in the present studies are lost upon suspension of GGF2 treatment over the course of 3-4 weeks. Of note, the inhibition of apoptosis of newly formed cardiomyocytes during this period cannot be ruled out. In addition to proliferation reported by Bersell and colleagues (Bersell et al., 2009; Ford et al., 1999) , Bian and colleagues (Bian et al., 2009) demonstrated that GGF2 treatment enhanced troponin content in mouse heart tissue following exposure to anthracyclines. Additionally, Hill and colleagues (Hill et al., 2013) found that GGF2 affected transcription of a variety of genes associated with cytoarchitecture as well as energy metabolism in rats with MI-induced heart failure. This observation was first made in vitro where neuregulins promoted protein synthesis and cytoarchitectural changes (Baliga et al., 1999; Sawyer et al., 2002) . Importantly, GGF2 has also been Fig. 8 . Effects of chronic once-every-2-week intravenous GGF2 treatment on EF, FS, and ESV in failing rat hearts. Intravenous dosing of vehicle (filled circles) or GGF2 (open circles) administered once every 2 weeks. The last dose was given at week 40. Normal mean parameter values for the experiment are indicated. Ventricular function was assessed echocardiographically once weekly for first month followed by once every month thereafter. Shown are mean (A) EF ± S.E.M., (B) FS ± S.E.M., and (C) ESV ± S.E.M.; (once-every-2-week dosing). Normal mean parameter values for the experiment are indicated. Data were compared by repeated measures one-way analysis of variance followed by a Dunnett's post-hoc test. EF, FS, and ESV were significantly improved with GGF2 treatment compared with vehicle over the treatment period (P < 0.05, Dunnett's). EF, ejection fraction; ESV, end-systolic volume; FS, fractional shortening; GGF2, glial growth factor 2; S.E.M., standard error of the mean.
shown to improve myocardial fibrosis, intercalated disk and sarcomere ultrastructure, and mitochondrial morphology in the failing heart (Galindo et al., 2014) . These findings suggest that the cytoarchitecture, contractile components, metabolic and proliferative/anti-apoptotic changes in cardiomyocytes under stress may be affected by neuregulin treatment. The long-lasting effects provided by GGF2 following cessation of dosing may reflect the turnover of proteins related to pleiotropic transcriptional changes induced by ErbB receptor stimulation.
The present studies also suggest that GGF2-induced improvements in LV function and remodeling are not related to effects on infarct size. Although GGF2 and other neuregulins have shown cardioprotective properties (Fukazawa et al., 2003; Rohrbach et al., 2005a; Timolati., 2006; Zhao et al., 1998; Bian et al., 2009; Lorita et al., 2009) , the permanent ischemic nature of the model and relatively long interval between MI and treatment initiation means that GGF2 would not be expected to preserve vulnerable cardiomyocytes in the peri-infarct area. Based on the results reported here and elsewhere (Bersell et al., 2009; Liu et al., 2006) , it appears that the neuregulin effect in this model is not attributable to cytoprotection. This is further supported by the robust improvement in LV function observed following substantial delay in the initiation of treatment post-MI.
Beyond improved muscle function, proliferation (Bian et al., 2009; Ford et al., 1999; Liu et al., 2006) , differentiation of stem cells, and precursors (Kim et al., 2007; Sun et al., 2011; Wang et al., 2009 ), reduction of inflammation following injury is another potential mechanism by which neuregulin may improve cardiac function. The ability of neuregulins to reduce inflammation in other systems is well documented (Dimayuga et al., 2003; Xu et al., 2005 Xu et al., , 2004 . There was no evidence of inflammation in either the vehicle-or GGF2-treated animal cardiac histology at 38 days post-ligation; however, closer examination of inflammation at times more proximal to injury is warranted. Further investigation into the potential mechanism(s) of action of LV-function improvement by systemic GGF2 treatment is underway in multiple laboratories.
Neuregulins are emerging as potential treatments for heart failure. GGF2 was chosen as a development candidate with potentially longlasting pharmacodynamic activity. In addition to the present studies, GGF2 has been manufactured under Good Manufacturing Practice conditions, completed initial preclinical safety evaluation studies, and has been studied in patients with heart failure (Lenihan et al., 2013) . Recently, transient dose-limiting liver findings were identified in early clinical studies. While liver-related serum chemistry changes were monitored in rats in Good Laboratory Practice pivotal toxicology studies, no adverse changes in transaminases or bilirubin were observed in this species. Therefore, liver-related serum chemistry parameters were not evaluated in the present study. However, recently conducted clinical trials as well as nonclinical investigative toxicology Fig. 9 . Effects of various dose levels of GGF2 administered once every 2 weeks on EF, FS, and ESV in failing rat hearts. Vehicle (filled gray circles) or GGF2 was dosed intravenously once every 2 weeks at 0.35 (open black circles), 0.875 (filled black circles), 1.75 (open black diamonds), and 3.5 mg/kg (filled black diamonds). The last dose was given at week 13. Ventricular function was assessed echocardiographically once weekly through 15 weeks after initiation of dosing. Shown are mean (A) EF ± S.E.M., (B) FS ± S.E.M., and (C) ESV ± S.E.M. Normal mean parameter values for the experiment are indicated. Data were compared by repeated measures one-way analysis of variance followed by a post-hoc Dunnett's test. EF and FS were significantly improved compared with vehicle at all dose levels with GGF2 treatment over the treatment period (P < 0.05). ESV was significantly improved at the highest dose level tested (P < 0.05). EF, ejection fraction; ESV, end-systolic volume; FS, fractional shortening; GGF2, glial growth factor 2; S.E.M., standard error of the mean. CL, clearance; Cpl 5 min , concentration in plasma at 5 min; GGF2, glial growth factor 2; ND, not determined; t 1/2 , half-life; Vd, volume of distribution.
T.J. Parry et al. European Journal of Pharmacology 796 (2017) 76-89 studies conducted in cynomolgus monkeys suggest that these changes may be due to nonobstructive cholestatic mechanisms and not overt hepatocyte toxicity (data not shown). Hence, clinical evaluation of GGF2 in heart-failure patients is expected to continue. It should be noted that GGF2 is not approved for any indication and human safety and efficacy data have not yet been established.
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